Physician profile
Peter L Stevenson
NPI 1003942822
$1,187.04
in general payments reported to CMS, 2019-2025
26 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $99.29 · 2021: $349 · 2022: $158 · 2023: $118 · 2024: $97.78 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $182.73 | 2019-2025 | |
| Myovant Sciences INC. | $169.24 | 2021 | |
| Daiichi Sankyo INC. | $129.16 | 2020-2025 | Injectafer |
| Therapeuticsmd, INC. | $76.80 | 2019-2022 | |
| Channel Medsystems, INC. | $63.93 | 2025 | |
| Pfizer INC. | $47.36 | 2024-2025 | |
| Avion Pharmaceuticals | $41.52 | 2019-2021 | |
| Astellas Pharma US INC | $40.77 | 2024 | Veozah |
| Mylan Pharmaceuticals INC. | $38.31 | 2022 | |
| Agile Therapeutics, INC. | $36.28 | 2021 | |
| Amag Pharmaceuticals, INC. | $34.32 | 2019 | |
| Evofem Biosciences, INC. | $32.47 | 2021 | |
| Hologic Sales and Service, LLC | $28.46 | 2020 | |
| Sumitomo Pharma America, INC. | $28.08 | 2023 | Myfembree |
| Ethicon US, LLC | $25.07 | 2025 | Dermabond, Vistaseal |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $25.04 | 2020 | |
| Abiomed | $24.73 | 2023 | Impella |
| Dysis Medical, INC. | $23.11 | 2021 | |
| Coopersurgical, INC. | $22.90 | 2023 | Paragard T 380a |
| Medtronic, INC. | $19.22 | 2023 | Interstim |
| Mayne Pharma Commercial LLC | $18.71 | 2022 | |
| Aspira Women'S Health INC | $17.27 | 2020 | |
| Shield Therapeutics INC | $17.01 | 2024 | |
| Becton, Dickinson and Company | $15.34 | 2024 | Bd Onclarity |
| Millicent US INC | $15.13 | 2025 | Femlyv |
| Exeltis, USA INC. | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.